查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602226

病毒載體和質體DNA 製造市場：按類型、細胞株、轉染、適應症、工作流程、應用、最終用戶 - 2025-2030 年全球預測

Viral Vector & Plasmid DNA Manufacturing Market by Type (Plasmid DNA, Viral Vector), Cell Line (In-vitro, In-Vivo), Transfection, Indication, Workflow, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

病毒載體質體DNA製造市場2023年估值為15億美元，預計到2024年將達18.8億美元，複合年成長率為25.34%，預計到2030年將達到73.2億美元。

在基因治療、疫苗和細胞療法需求不斷成長的推動下，病毒載體和質體DNA 製造業在生物製藥中發揮著至關重要的作用。此領域包括病毒載體的生產（將遺傳物質傳遞到細胞中的工具）和質體DNA（作為基因治療和 DNA 疫苗生產的模板）。由於遺傳疾病和癌症治療的興起，尤其是最近 COVID-19 引起的對疫苗開發的關注，這種製造變得至關重要。應用範圍包括基因治療、疫苗開發，甚至增強農業生物技術。該領域重點支持生物技術公司、研究機構和製藥公司等最終用戶。影響市場成長的關鍵因素包括基因工程技術的進步、生物技術研究資金的增加以及促進創新治療方法快速推出的監管核准。可擴展的製造流程以及生物技術公司和受託製造廠商(CMO) 之間的合作有很多機會，特別是在個人化醫療領域。挑戰包括高製造成本、嚴格的法律規範以及大規模基因治療製造的複雜性。圍繞基因改造的潛在安全問題和倫理考量也產生了限制。儘管有這些挑戰，但仍有一些領域有利於創新，特別是在流程最佳化和自動化方面，以降低成本並提高效率。對 CRISPR 技術和次世代定序儀的投資也可以突破基因治療的極限。此外，建立強大的供應鏈框架可以顯著緩解生產瓶頸。市場的動態本質以快速的技術進步和法規環境為特徵，為尋求利用尖端治療方法的相關人員帶來了挑戰和機會。在應對複雜的監管環境的同時負責任地擁抱這些創新將是這個快速發展的行業實現持續成長和有影響力的突破的關鍵。

主要市場統計
基準年[2023] 15億美元
預測年份 [2024] 18.8億美元
預測年份 [2030] 73.2億美元
複合年成長率（%） 25.34%

市場動態：快速發展的病毒載體和質體DNA 製造市場的關鍵市場洞察

供需的動態交互作用正在改變病毒載體和質體DNA 製造市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球基因治療臨床試驗增加
    • 分子生物學技術的進展
  • 市場限制因素
    • 病毒載體和質體DNA 解決方案的製造成本較高
  • 市場機會
    • 擴大引入新型病毒載體和質體DNA 解決方案
    • 增加對個人化醫療的投資
  • 市場挑戰
    • 對基因治療產品安全性和有效性的擔憂

波特五力：引領病毒載體與質體DNA 製造市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解病毒載體和質體DNA製造市場的外部影響

外部宏觀環境因素在塑造病毒載體質體DNA 製造市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解病毒載體/質體DNA 製造市場的競爭狀況

病毒載體質體DNA 製造市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣病毒載體與質體DNA製造市場供應商的績效評估

FPNV定位矩陣是評估病毒載體和質體DNA製造市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類了供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球基因治療臨床試驗數量增加
      • 分子生物學技術的進展
    • 抑制因素
      • 病毒載體和質體DNA 解決方案的製造成本較高
    • 機會
      • 更多關於新型病毒載體和質體DNA 解決方案的介紹
      • 增加對個人化醫療的投資
    • 任務
      • 對基因治療產品安全性和有效性的擔憂
  • 市場區隔分析
    • 細胞株：在受控實驗室環境中增加體外細胞株的使用
    • 類型：對質體DNA 製造的需求不斷增加，以將遺傳物質傳遞給細胞
    • 轉染：穩定轉染在基因治療和藥物開發中日益普及
    • 最終用戶：在製藥和生物製藥公司中擴大病毒載體和質體DNA 的潛力，用於下一代疫苗的開發和製造
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章病毒載體/質體DNA 製造市場：依類型

  • 質體DNA
  • 病毒載體
    • 腺結合病毒
    • 腺病毒
    • 慢病毒

第 7 章 依細胞株的病毒載體/質體DNA 製造市場

  • 試管內
  • 體內

第8章轉染病毒載體/質體DNA製造市場

  • 穩定轉染
  • 瞬時轉染

第9章依適應症分類的病毒載體/質體DNA製造市場

  • 癌症
  • 遺傳疾病
  • 感染疾病

第 10 章病毒載體/質體DNA 製造市場：依工作流程

  • 下游加工
    • 填充完成
    • 精製
  • 上游加工
    • 向量放大和擴展
    • 載體收集/收穫

第11章病毒載體/質體DNA 製造市場：依應用分類

  • 細胞療法
  • 基因治療
  • 疫苗學

第12章病毒載體/質體DNA 製造市場：依最終用戶分類

  • 製藥和生物製藥公司
  • 調查機構

第13章北美和南美的病毒載體和質體DNA製造市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第14章亞太地區病毒載體及質體DNA製造市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第15章歐洲、中東和非洲的病毒載體和質體DNA製造市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Ajinomoto Co., Inc.以6.2億美元收購Forge Biologics
    • Genezen 獲得 1,850 萬美元的成長資本，以擴大病毒載體的開發和製造能力
    • CCRM 與 Membio 合作，簡化細胞和基因治療病毒載體的生產

公司名單

  • Charles River Laboratories International, Inc.
  • GE HealthCare Technologies, Inc.
  • Biovian Oy
  • c-LEcta GmbH
  • Batavia Biosciences BV
  • Thermo Fisher Scientific Inc.
  • Takara Bio Inc.
  • Avid Bioservices, Inc.
  • Wuxi AppTec Co., Ltd.
  • PerkinElmer Inc.
  • REGENXBIO Inc.
  • Lonza Group Ltd.
  • Advanced BioScience Laboratories, Inc.
  • Miltenyi Biotec BV & Co. KG
  • Genezen Laboratories, Inc.
  • FILTROX AG
  • Genezen
  • Merck KGaA
  • Akron Biotech
  • uniQure NV
  • Kaneka Eurogentec SA
  • BioNTech IMFS GmbH
  • Creative Biogene
  • Forge Biologics By Ajinomoto Co., Inc.
  • Spark Therapeutics, Inc.
  • FUJIFILM Diosynth Biotechnologies Inc.
  • GeneOne Life Science, Inc.
Product Code: MRR-030298DFFC33

The Viral Vector & Plasmid DNA Manufacturing Market was valued at USD 1.50 billion in 2023, expected to reach USD 1.88 billion in 2024, and is projected to grow at a CAGR of 25.34%, to USD 7.32 billion by 2030.

The viral vector and plasmid DNA manufacturing sector plays a pivotal role in biopharmaceuticals, driven by the increasing demand for gene therapies, vaccines, and cell therapies. It encompasses the production of viral vectors, which are tools for delivering genetic material into cells, and plasmid DNA, which serves as a template for gene therapy and DNA vaccine production. Such manufacturing is essential due to the rise in genetic disorders, cancer therapies, and the recent spotlight on vaccine development, particularly in the wake of COVID-19. Applications span across gene therapy, vaccine development, and even in enhancing agricultural biotechnologies. The sector prominently supports end-users such as biotech companies, research institutes, and pharmaceutical firms. Key factors influencing market growth include advancements in genetic engineering techniques, increased funding for biotech research, and regulatory approvals facilitating the faster introduction of innovative therapies. Opportunities abound in scalable manufacturing processes and collaboration between biotech companies and Contract Manufacturing Organizations (CMOs), especially for personalized medicine. Challenges include high production costs, stringent regulatory frameworks, and complexity in large-scale gene therapy production. Limitations also arise from potential safety concerns and ethical considerations surrounding genetic modifications. Despite these challenges, there are lucrative areas for innovation, notably in process optimization and automation to reduce costs and improve efficiency. Investment in CRISPR technology and next-gen sequencing can also push the boundary of what's achievable in genetic therapy. Moreover, developing robust supply chain frameworks can significantly alleviate production bottlenecks. The market's dynamic nature, characterized by rapid technological advancements and regulatory environments, presents both a challenge and an opportunity for stakeholders looking to leverage cutting-edge therapies. Embracing these innovations responsibly while navigating the intricate regulatory landscape will be key for sustained growth and impactful breakthroughs in this rapidly evolving industry.

KEY MARKET STATISTICS
Base Year [2023] USD 1.50 billion
Estimated Year [2024] USD 1.88 billion
Forecast Year [2030] USD 7.32 billion
CAGR (%) 25.34%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Viral Vector & Plasmid DNA Manufacturing Market

The Viral Vector & Plasmid DNA Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing number of gene therapy clinical trials worldwide
    • Growing advancement in molecular biology technologies
  • Market Restraints
    • High cost of manufacturing of viral vector & plasmid DNA solutions
  • Market Opportunities
    • Growing introduction of novel viral vector & plasmid DNA solutions
    • Rising investment in personalized medicine
  • Market Challenges
    • Concerns regarding the safety and efficacy of gene therapy products

Porter's Five Forces: A Strategic Tool for Navigating the Viral Vector & Plasmid DNA Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Viral Vector & Plasmid DNA Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Viral Vector & Plasmid DNA Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Viral Vector & Plasmid DNA Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Viral Vector & Plasmid DNA Manufacturing Market

A detailed market share analysis in the Viral Vector & Plasmid DNA Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Viral Vector & Plasmid DNA Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Viral Vector & Plasmid DNA Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Viral Vector & Plasmid DNA Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Charles River Laboratories International, Inc., GE HealthCare Technologies, Inc., Biovian Oy, c-LEcta GmbH, Batavia Biosciences B.V., Thermo Fisher Scientific Inc., Takara Bio Inc., Avid Bioservices, Inc., Wuxi AppTec Co., Ltd., PerkinElmer Inc., REGENXBIO Inc., Lonza Group Ltd., Advanced BioScience Laboratories, Inc., Miltenyi Biotec B.V. & Co. KG, Genezen Laboratories, Inc., FILTROX AG, Genezen, Merck KGaA, Akron Biotech, uniQure N.V., Kaneka Eurogentec S.A., BioNTech IMFS GmbH, Creative Biogene, Forge Biologics By Ajinomoto Co., Inc., Spark Therapeutics, Inc., FUJIFILM Diosynth Biotechnologies Inc., and GeneOne Life Science, Inc..

Market Segmentation & Coverage

This research report categorizes the Viral Vector & Plasmid DNA Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Plasmid DNA and Viral Vector. The Viral Vector is further studied across Adeno-Associated Virus, Adenovirus, and Lentivirus.
  • Based on Cell Line, market is studied across In-vitro and In-Vivo.
  • Based on Transfection, market is studied across Stable Transfection and Transient Transfection.
  • Based on Indication, market is studied across Cancer, Genetic Disorder, and Infectious Disease.
  • Based on Workflow, market is studied across Downstream Processing and Upstream Processing. The Downstream Processing is further studied across Fill-finish and Purification. The Upstream Processing is further studied across Vector Amplification & Expansion and Vector Recovery/Harvesting.
  • Based on Application, market is studied across Cell Therapy, Gene Therapy, and Vaccinology.
  • Based on End User, market is studied across Pharmaceutical & Biopharmaceutical Companies and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing number of gene therapy clinical trials worldwide
      • 5.1.1.2. Growing advancement in molecular biology technologies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of manufacturing of viral vector & plasmid DNA solutions
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing introduction of novel viral vector & plasmid DNA solutions
      • 5.1.3.2. Rising investment in personalized medicine
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding the safety and efficacy of gene therapy products
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Cell Line: Growing usage of in-vitro cell lines in controlled laboratory environments
    • 5.2.2. Type: Increasing need for plasmid DNA manufacturing to deliver genetic material into cells
    • 5.2.3. Transfection: Rising popularity of stable transfection for gene therapy and drug development
    • 5.2.4. End User: Expanding the potential of viral vectors & plasmid DNA across pharmaceutical & biopharmaceutical companies for the development and production of next-generation vaccines
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Viral Vector & Plasmid DNA Manufacturing Market, by Type

  • 6.1. Introduction
  • 6.2. Plasmid DNA
  • 6.3. Viral Vector
    • 6.3.1. Adeno-Associated Virus
    • 6.3.2. Adenovirus
    • 6.3.3. Lentivirus

7. Viral Vector & Plasmid DNA Manufacturing Market, by Cell Line

  • 7.1. Introduction
  • 7.2. In-vitro
  • 7.3. In-Vivo

8. Viral Vector & Plasmid DNA Manufacturing Market, by Transfection

  • 8.1. Introduction
  • 8.2. Stable Transfection
  • 8.3. Transient Transfection

9. Viral Vector & Plasmid DNA Manufacturing Market, by Indication

  • 9.1. Introduction
  • 9.2. Cancer
  • 9.3. Genetic Disorder
  • 9.4. Infectious Disease

10. Viral Vector & Plasmid DNA Manufacturing Market, by Workflow

  • 10.1. Introduction
  • 10.2. Downstream Processing
    • 10.2.1. Fill-finish
    • 10.2.2. Purification
  • 10.3. Upstream Processing
    • 10.3.1. Vector Amplification & Expansion
    • 10.3.2. Vector Recovery/Harvesting

11. Viral Vector & Plasmid DNA Manufacturing Market, by Application

  • 11.1. Introduction
  • 11.2. Cell Therapy
  • 11.3. Gene Therapy
  • 11.4. Vaccinology

12. Viral Vector & Plasmid DNA Manufacturing Market, by End User

  • 12.1. Introduction
  • 12.2. Pharmaceutical & Biopharmaceutical Companies
  • 12.3. Research Institutes

13. Americas Viral Vector & Plasmid DNA Manufacturing Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Ajinomoto Co., Inc. to Acquire Forge Biologics for USD 620 Million
    • 16.3.2. Genezen Secures USD 18.5 Million in Growth Equity to Expand Viral Vector Development and Manufacturing Capabilities
    • 16.3.3. CCRM Partners with Membio to Streamline Production of Viral Vectors for Cell and Gene Therapies

Companies Mentioned

  • 1. Charles River Laboratories International, Inc.
  • 2. GE HealthCare Technologies, Inc.
  • 3. Biovian Oy
  • 4. c-LEcta GmbH
  • 5. Batavia Biosciences B.V.
  • 6. Thermo Fisher Scientific Inc.
  • 7. Takara Bio Inc.
  • 8. Avid Bioservices, Inc.
  • 9. Wuxi AppTec Co., Ltd.
  • 10. PerkinElmer Inc.
  • 11. REGENXBIO Inc.
  • 12. Lonza Group Ltd.
  • 13. Advanced BioScience Laboratories, Inc.
  • 14. Miltenyi Biotec B.V. & Co. KG
  • 15. Genezen Laboratories, Inc.
  • 16. FILTROX AG
  • 17. Genezen
  • 18. Merck KGaA
  • 19. Akron Biotech
  • 20. uniQure N.V.
  • 21. Kaneka Eurogentec S.A.
  • 22. BioNTech IMFS GmbH
  • 23. Creative Biogene
  • 24. Forge Biologics By Ajinomoto Co., Inc.
  • 25. Spark Therapeutics, Inc.
  • 26. FUJIFILM Diosynth Biotechnologies Inc.
  • 27. GeneOne Life Science, Inc.

LIST OF FIGURES

  • FIGURE 1. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STABLE TRANSFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSIENT TRANSFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENETIC DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FILL-FINISH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VECTOR AMPLIFICATION & EXPANSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VECTOR RECOVERY/HARVESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 176. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 185. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 186. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 195. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 205. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 206. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 215. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 216. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 225. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 226. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 244. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 246. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 247. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 248. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 256. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 257. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 258. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 264. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 266. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 267. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 268. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 276. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
  • TABLE 277. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
  • TABLE 278. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 284. GERMANY VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. GERMANY VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD